- Home
- TACT vs SNTI Comparison
TACT vs SNTI Comparison
Compare TACT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- SNTI
- Stock Information
- Founded
- TACT 1996
- SNTI 2016
- Country
- TACT United States
- SNTI United States
- Employees
- TACT N/A
- SNTI N/A
- Industry
- TACT Computer peripheral equipment
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- TACT Technology
- SNTI Health Care
- Exchange
- TACT Nasdaq
- SNTI Nasdaq
- Market Cap
- TACT 42.2M
- SNTI 39.6M
- IPO Year
- TACT 1996
- SNTI N/A
- Fundamental
- Price
- TACT $4.63
- SNTI $1.39
- Analyst Decision
- TACT Strong Buy
- SNTI Strong Buy
- Analyst Count
- TACT 1
- SNTI 2
- Target Price
- TACT $5.00
- SNTI $8.50
- AVG Volume (30 Days)
- TACT 68.6K
- SNTI 123.0K
- Earning Date
- TACT 11-06-2025
- SNTI 11-13-2025
- Dividend Yield
- TACT N/A
- SNTI N/A
- EPS Growth
- TACT N/A
- SNTI N/A
- EPS
- TACT N/A
- SNTI N/A
- Revenue
- TACT $47,949,000.00
- SNTI N/A
- Revenue This Year
- TACT $21.67
- SNTI N/A
- Revenue Next Year
- TACT $7.63
- SNTI $150.00
- P/E Ratio
- TACT N/A
- SNTI N/A
- Revenue Growth
- TACT N/A
- SNTI N/A
- 52 Week Low
- TACT $3.12
- SNTI $1.26
- 52 Week High
- TACT $4.89
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- TACT 64.75
- SNTI 38.48
- Support Level
- TACT $4.09
- SNTI $1.33
- Resistance Level
- TACT $4.76
- SNTI $1.39
- Average True Range (ATR)
- TACT 0.18
- SNTI 0.08
- MACD
- TACT -0.00
- SNTI 0.01
- Stochastic Oscillator
- TACT 80.64
- SNTI 37.14
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.